These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1074 related articles for article (PubMed ID: 9198890)
1. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors]. Tschudi MR; Noll G; Lüscher TP Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890 [TBL] [Abstract][Full Text] [Related]
2. [Molecular and cellular mechanisms of arteriosclerosis and restenosis: possibilities of gene therapy]. Lüscher TF; Oemar BS; Yang Z; Noll G Z Kardiol; 1996 Jul; 85(7):495-508. PubMed ID: 8928548 [TBL] [Abstract][Full Text] [Related]
3. [Molecular medicine and gene therapy as exemplified with arteriosclerosis and restenosis]. Lüscher TF; Oemar BS; Yang Z; Noll G Schweiz Med Wochenschr; 1995 Nov; 125(44):2107-21. PubMed ID: 7502010 [TBL] [Abstract][Full Text] [Related]
4. Vascular protection: current possibilities and future perspectives. Lüscher TF Int J Clin Pract Suppl; 2001 Jan; (117):3-6. PubMed ID: 11715356 [TBL] [Abstract][Full Text] [Related]
5. Optimal medical management of peripheral arterial disease. Rice TW; Lumsden AB Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725 [TBL] [Abstract][Full Text] [Related]
6. Endothelial dysfunction in human disease. Drexler H; Hornig B J Mol Cell Cardiol; 1999 Jan; 31(1):51-60. PubMed ID: 10072715 [TBL] [Abstract][Full Text] [Related]
13. Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro. Kreuzer J; Watson L; Herdegen T; Loebe M; Wende P; Kübler K Eur J Med Res; 1999 Apr; 4(4):135-43. PubMed ID: 10205288 [TBL] [Abstract][Full Text] [Related]
14. The effects of ACE inhibition on progression of atherosclerosis. Sharpe N J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S9-12. PubMed ID: 7514240 [TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
16. [The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease]. Halawa B Pol Merkur Lekarski; 1998 Jan; 4(19):32-4. PubMed ID: 9553407 [TBL] [Abstract][Full Text] [Related]
17. [Statins have other beneficial properties besides their cholesterol lowering effect]. Eriksson M Lakartidningen; 1998 Aug; 95(35):3670-2. PubMed ID: 9748780 [TBL] [Abstract][Full Text] [Related]
18. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits. Weckler N; Leitzbach D; Kalinowski L; Malinski T; Busch AE; Linz W J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):191-6. PubMed ID: 14608526 [TBL] [Abstract][Full Text] [Related]
19. Endothelium dysfunction in the coronary circulation. Lüscher TF; Noll G J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S16-26. PubMed ID: 7700060 [TBL] [Abstract][Full Text] [Related]
20. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials]. Wojakowski W; Gmiński J Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]